SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sugen (SUGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: EPro who wrote (458)6/5/1999 10:35:00 PM
From: Miljenko Zuanic  Read Replies (1) of 550
 
<<Food and Drug Administration Signs Off on SUGEN's Clinical Strategy to Move Directly Into Phase III Trials With SU5416, Lead Angiogenesis Inhibitor>>

It means that small multiple PI/II trials (5416 + chemo) are going well and that there is no concern (at least not for now) about combined toxicity.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News